Milestone Pharmaceuticals Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR | Milestone Pharmaceuticals, Inc.

Milestone Pharmaceuticals Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR

November 13, 2023 at 8:00 AM EST

Listen to Webcast

Supporting Materials

Milestone Pharmaceuticals Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR Presentation 2.6 MB

Print Page

RSS Feeds

Email Alerts

Investor Contact

Search